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Aims. Chondroid lipoma (CL) is a benign tumor that mimics a variety of soft tissue tumors and is characterized by translocation
t(11;16). Here, we analyze CL and its histological mimics. Methods. CL (n = 4) was compared to a variety of histological mimics
(n = 83) formorphological aspects and immunohistochemical features including cyclinD1(CCND1). Using FISH analysis,CCND1
and FUS were investigated as potential translocation partners. Results. All CLs were strongly positive for CCND1. One of 4 myoep-
itheliomas, CCND1, was positive. In well-diﬀerentiated lipomatous tumors and in chondrosarcomas, CCND1 was frequently
expressed, but all myxoid liposarcomas were negative. FISH analysis did not give support for direct involvement of CCND1 and
FUS as translocation partners. Conclusions. Chondroid lipoma is extremely rare and has several and more prevalent histological
mimics. The diﬀerential diagnosis of chondroid lipomas can be unraveled using immunohistochemical and molecular support.
1. Introduction
Lipomatous lesions show a broad morphological spectrum
and clinically range from benign to highly malignant dis-
eases. Over the last few years, studies focusing on lipoma-
tous tumors have led to the delineation of new variants of
lipomatous proliferations as well as to the introduction of
new concepts, mainly as a result of the fruitful interactions
between molecular genetics and pathology [1–4]. As a result,
chondroid lipoma has been described and considered a
benign tumor of soft tissue that may mimic a variety of soft
tissue tumors [1, 5–7].
At gross examination, chondroid lipoma resembles
lipoma, presenting as a solitary, slowly growing mass that
is located either within skeletal muscle, muscle fascia, or in
the deep subcutis. The main cytological features consist of
clustered, variably mature, multivacuolated hibernoma-like
cells enmeshed in a capillary plexus, in a background of
chondromyxoid material. This tumor may show histologic
features resembling myoepithelioma, myxoid liposarcoma,
extraskeletal myxoid chondrosarcoma, hibernoma, and other
lipomatous or chondroid neoplasms, resulting in diagnostic
and consequently therapeutic dilemmas [8].
Cytogenetic data on a few cases of chondroid lipoma
are available and show a balanced translocation t(11;16)
(q13-p12) [9–11]. The typical and recurrent involvement of
11q13 has also been described in other classes of lipomatous
tumors such as ordinary lipoma and hibernoma, but not in
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association with 16p12-13. Several genes at the breakpoint
regions may be relevant candidate genes, and recently MKL/
myocardin-like 2 (MKL2) has been implicated. Recent find-
ings show that cyclinD1 (CCND1) is not only involved in cell
cycle regulation, but also in the regulation of cellularmetabo-
lism, cellular migration, and especially fat cell diﬀerentiation,
making this a relevant candidate gene [12]. Another candi-
date fusion gene is the FUS gene located on chromosome
16p11. This gene is involved in one of the typical mimics
of chondroid lipomas: myxoid liposarcoma. Although FUS
is located at a diﬀerent chromosomal location (16p11 versus
16p12) and therefore involvement in chondroid lipomas is
not highly likely, it has not been properly investigated.
Here, we describe a histopathological, immunohisto-
chemical and fluorescence in situ hybridization analysis in a
series of chondroid lipomas and histological mimics.
2. Methods
To retrieve all cases diagnosed as chondroid lipomas in the
Netherlands between 1997 and 2007, a search was performed
in the Dutch nationwide pathology registry database (Patho-
logic Anatomic National Automated Archive, PALGA). The
PALGA database contains all reports of potential cases
and anonymous patient characteristics such as age, gender,
conclusions, and coded summaries of all pathology reports
in the Netherlands since 1992. Potential cases were retrieved
and corresponding formalin fixed paraﬃn embedded tissue
blocks were collected from the original pathology labo-
ratories. Eleven cases were reviewed on hematoxylin and
eosin-stained slides with additional immunohistochemical
and molecular data if needed (RdV, DdJ and JB); consensus
was obtained at the multiheadedmicroscope. Two additional
cases of chondroid lipoma were retrieved from the files of the
Department of Dermatology, Bodensee, Friedrichshafen (Dr.
T.Mentzel) and also included for further study. Classification
of all biopsy and resection material was performed according
to the WHO classification for soft tissue tumors [13]. Four
cases were diagnosed as chondroid lipoma four cases as
myoepithelioma and selected for further study. The remain-
ing cases were diagnosed as myxoid liposarcoma (n = 1),
lipoma (n = 1), and hibernoma (n = 1), chondrolipoma
(n = 2).
Specifically, to further investigate the role of CCND1 in
the spectrum of lipomatous tumors, 21 lipomas, 28 well-
diﬀerentiated liposarcomas, 18 myxoid liposarcomas, and 10
chondrosarcomas, both extraskeletal myxoid chondrosarco-
mas and primary chondrosarcomas of bone with extension
into the soft tissue that were diagnosed in the same period,
were randomly selected from the files of the Netherlands
Cancer Institute to complete the morphological spectrum.
2.1. Immunohistochemical Analysis. Immunohistochemical
staining was performed according to standard methods. In
brief, after a pretreatment of citrate-based microwave antigen
retrieval, the sections were incubated with the following anti-
bodies overnight at 4◦C without pretreatment: CCND1 anti-
body (SP-4 AB-5 Labvision, Fremont, USA) dilution 1 : 100,
CD34 antibody (QBEND Labvision, Fremont, USA) dilution
1 : 3000,CD68 antibody (KP1 DAKOGlostrup Denmark) di-
lution 1 : 50000, S100 antibody (polyclonal DAKO Glostrup
Denmark) dilution 1 : 6000, Pan Keratin antibody (MNF116
+ LP34 DAKO Glostrup Denmark) dilution 1 : 1600, P63
antibody (MNF116 + LP34 LabVission Fremont USA)
dilution 1 : 5000, SMA antibody (1A4 Zymed Carlsbad USA)
dilution 1 : 5, vimentin antibody (3B4 DAKO Glostrup
Denmark) dilution 1 : 400 and visualized with diaminoben-
zidine. The percentage of tumor cells with nuclear stain-
ing was assessed semiquantitatively. Staining intensity was
ranked in three levels (positive, focal positive, and negative).
Immunohistochemical staining of all slides were scored by
two observers (DdJ and RdV). Slides could only be scored
negative if positive internal controls were present. In cases
of discrepancies or equivocal interpretations, consensus was
obtained at the multiheaded microscope.
2.2. Fluorescence in Situ Hybridization. After confirming
the most histologically typical areas using hematoxylin
and eosin stained sections, dual-colour fluorescence in situ
hybridization assay was performed according to standard
methods on 5-µm-thick tissue sections of formalin fixed
paraﬃn embedded specimens. After dewaxing, hydration,
and pretreatment (DAKO Glostrup Denmark) at 95◦C for
10min, a protease digestion was performed in for 15min at
37◦C. Incubation was performed according to the dual-color
break-apart principle with two diﬀerently labeled probes
flanking the gene of interest. For CCND1, one Texas Red-
labeled DNA probe (CCND1-Upstream) covering 163 kb
centromeric to the CCND1 breakpoint cluster region and
one fluorescein-labeled DNA probe (CCND1-Downstream)
covering 644 kb telomeric to the CCND1 breakpoint cluster
region were cohybridized (DAKO Glostrup Denmark). For
analysis of FUS (16p11), one Spectrum Green labeled probe
distal to the FUS gene and one Spectrum Orange labeled
probe proximally from the FUS gene were used. Slides were
incubated at 37◦C for 48 h in a humidified chamber. After
stringent washing at 72◦C for 2min and counterstaining,
fluorescent signals were scored using a Nikon Microphot-
SA fluorescence microscope with appropriate filters, and
the resulting images were captured using a charge-coupled-
device camera. Fifty to 60 evaluable nuclei were counted by
two diﬀerent individuals (PN and RdV), and the percentages
of single and fused signals were calculated. A positive result
was defined as the presence of split signals in more than 10%
of the cells when the distance between the flanking signals
was three times the estimated signal diameter. In case of two
single color pairs in more than 90% of the cells, cells were
regarded negative for translocation.
3. Results
3.1. Patient Selection. In the initial PALGA and the Bodensee,
Friedrichshafen (Dr. T. Mentzel) selection, 15 patients were
retrieved. Of these, 2 cases were excluded because repre-
sentative material could not be obtained. At review, four
lesions were considered true chondroid lipomas. Further,
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Table 1: Patient and tumor characteristics.
Patient characteristics Chondroid
lipoma
Myo
epithelioma
lipoma
Well-
diﬀerentiated
liposarcoma
Myxoid
liposarcoma
Chondrosarcoma
Male/female 1/3 3/1 11/10 13/15 10/8 8/2
Median age at Diagnose, yrs (range) 36 (32–75) 56 (48–64) 49 (21–69) 62 (28–80) 43 (26–70) 54 (29–90)
Mean tumor circumference (range) 3 (2–10) 8 (2–20) 5 (1–18) 13,5 (2–30) 14 (4–30) 6 (2–13)
HEHE CCND1 S100 Keratin FISH CCND1 FISH FUS
(a)
HEHE CCND1 S100 Keratin FISH CCND1 FISH FUS
(b)
Figure 1: (a) Chondroid lipoma and (b) myoepithelioma.
four myoepitheliomas: one myxoid liposarcoma, one lipoma,
one hibernoma, and two chondro lipomas were diagnosed
(Table 1). The four chondroid lipomas and four myoepithe-
liomas were further analyzed and compared to 83 mimics
randomly selected cases collected at the Netherlands Cancer
Institute as described above.
3.2. Histopathological Analysis. Chondroid lipomas (n = 4)
showed fibrous capsule and were dominated by a mature
lipomatous proliferation with sheets, clusters, and nests
of cells with eosinophilic, vacuolated cytoplasm in an
eosinophilic cartilagenous matrix. The extracellular myxo-
hyaline matrix showed a cartilagenous appearance, and the
vascularisation was rich (Figure 1). The eosinophilic and
vacuolated tumor cells were arranged in sheets, clusters,
and cords and contain irregular, hyperchromatic nuclei with
inconspicuous nucleoli; some of the vacuolated cells are
indistinguishable from lipoblasts. Mitotic activity was absent.
3.3. Immunohistochemical Analysis. All (4/4) myoepithe-
liomas stained positive for keratin, whereas 1/4 chondroid
lipoma stained focally positive and 3/4 stained negative.
Immunohistochemical staining with S100 showed 1/4 pos-
itive and 2/4 focal positive lesions in chondroid lipoma
and 3/4 positive and 1/4 focal positive myoepithelioma.
Immunohistochemical staining of chondroid lipomas and
myoepithelioma for vimentin, SMA, CD34, CD68, and P53
was not distinctive.
Detailed immunohistochemical results are listed in
Table 2 and Figure 1.
3.4. CCND1 and FUS as Candidate Genes for Translocation
in Chondroid Lipoma. In all chondroid lipomas, both the
obvious lipogenic cells and the eosinophilic tumor cells were
immunohistochemically uniformly positive for CCND1,
whereas 1/4 myoepitheloma lesion stained positive for
CCND1, and 3/10 chondrosarcomas stained positive while
3/10 were focal positive and 4/10 were negative. The lipomas
and well-diﬀerentiated liposarcomas that were immunohis-
tochemically analyzed for CCND1 showed scattered positiv-
ity in a majority of cases 32/49 (65%), whereas 16/49 (33%)
stained negative for CCND1 and 1/49 stained positive. None
of the 18 myxoid liposarcomas showed immunohistochem-
ically CCND1 expression. Therefore, CCND1 could be used
for distinction between myxoid liposarcoma and chondroid
lipoma: 4/4 (100%) positivity in chondroid lipoma and 0/18
(0%) positivity in myxoid liposarcoma.
By using fluorescence in situ hybridization for CCND1
and FUS, respectively, no breaks in these genes could be
detected in chondroid lipoma or in myoepithelioma.
4. Discussion
This study shows that true chondroid lipomas are extremely
rare soft tissue tumors. The fact that in a Dutch nationwide
search in a 10-year period by PALGA only two unequivocal
cases were diagnosed that were retrieved within a spectrum
of mimics underlines the rarity of the diagnosis and shows
that awareness of the characteristics of chondroid lipoma
is particularly important in reaching a chondroid lipoma
diagnosis.
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Table 2: Immunohistochemical and fluorescence in situ hybridization results.
Histology
IHC IHC IHC IHC IHC IHC IHC IHC FISH FISH
CCND1 (%) CD34 CD68 S100 keratin P63 SMA vimentin Split apart CCND1 Split apart FUS
Chondroid lipoma (n = 4)
Positive 4 0 0 1 0 0 0 3 0 0
Focal positive 0 0 1 2 2 0 0 0 n.a. n.a.
Negative 0 4 3 1 2 4 4 1 4/4∗ 4/4∗
Myoepithelioma (n = 4)
Positive 1 0 0 3 3 0 0 4 0 0
Focal positive 1 0 1 1 1 1 0 0 n.a. n.a.
Negative 2 4 3 0 0 3 4 0 4/4∗ 3/3∗
Lipoma (n = 21)
Positive 0 — — — — — — — — —
Focal positive 16 (76) — — — — — — — — —
Negative 5 (24) — — — — — — — — —
Well diﬀerentiated liposarcoma
(n = 28)
Positive 1 (4) — — — — — — — — —
Focal positive 16 (57) — — — — — — — — —
Negative 11 (39) — — — — — — — — —
Myxoid liposarcoma (n = 18)
Positive 0 — — — — — — — — —
Focal positive 0 — — — — — — — — —
Negative 18 (100) — — — — — — — — —
Chondrosarcoma (n = 10)
Positive 3 (30) — — — — — — — — —
Focal positive 3 (30) — — — — — — — — —
Negative 4 (40) — — — — — — — — —
∗
There were no translocations observed.
n.a.: not applicable.
IHC: immunohistochemical.
This study furthermore shows that the histological mim-
ics of chondroid lipomas as described in the literature can
be distinguished bymeans of immunohistochemical analysis.
Especially immunohistochemistry for CCND1 and FISH
analysis for the specific translocations may be supportive
to discriminate between myxoid liposarcoma and chondroid
lipoma. Although some apparent histologic hallmarks of
chondroid lipomas can be readily recognized such as nests
and cords of uni- and multivacuolated cells within a promi-
nent myxohyaline to chondroid matrix, the immunohisto-
chemical marker pattern is very helpful. Myoepithelioma of
the soft tissues is an important mimic that expresses, in
contrast to chondroid lipoma, the epithelial markers keratin
as well as S100 protein. Well-diﬀerentiated liposarcoma with
myxoid changes may be a mimic that may be recognized
on the basis of clinical setting, morphology as well as by
the specific genetic changes. Also chondroid lipoma may be
characterized by a specific translocation t(11;16). Recently,
MKL/myocardin-like 2 (MKL2) and C11orf95 (chromosome
11 open reading frame 95) were identified as translocation
partners in 3 cases of chondroid lipoma. Although the extent
of possible variant translocations may not be clear yet, this
finding provides an important addition for further support
in diﬀerential diagnostic problems [11, 14]. In the present
study, all cases of chondroid lipomas showed high immuno-
histochemical expression of CCND1. Since the CCND1 gene
is located on 11q13, this makes it an attractive candidate
gene for the t(11;16) translocation in chondroid lipoma.
Based on a spilt apart FISH assay, CCND1 did not show
rearrangement, however. This indicates that the breakpoint
is most probably not located in the CCND1 region and
does not give support for involvement of this gene in the
oncogenesis of chondroid lipoma, despite expression of the
protein. Indeed, CCND1 is expressed broadly in several types
of well-diﬀerentiated lipomatous tumors, such as lipoma
and well-diﬀerentiated liposarcoma and also in tumors with
chondroid diﬀerentiation, including extraskeletal myxoid
chondrosarcoma and primary chondrosarcoma of bone in
support of this notion. As expected, FUS indeed was shown
not be involved in the translocation.
5. Conclusion
Chondroid lipoma is extremely rare and has several and
more prevalent histological mimics. The diﬀerential diagno-
sis of chondroid lipomas can be unraveled using immuno-
histochemical and molecular support. Although chondroid
lipoma shows high expression of CCND1, this expression
Sarcoma 5
should not be regarded as deregulated and there is no
support that CCND1 is directly involved as a translocation
partner in the characteristic t(11;16).
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